CTIS2023-509451-14-00招募中1 期
As Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas - CDYP688A12101
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients in the dose escalation part must be = 18 years of age at the time of informed consent (ICF) signature. In the phase II part, patients = 12 years of age at the time of informed consent may be eligible for enrollment (not applicable in countries where enrollment is restricted by the local health authority to patients = 18 years of age). Patients must have a minimum weight of 40 kg. For the 32 mg/kg dose level, a maximum weight limit of 115 kg may not be exceeded., ECOG performance status = 1 for patients = 18 years of age; Karnofsky performance status = 70 for patients = 16 and < 18 years of age; Lansky performance status = 70 for patients = 12 and < 16 years of age., Patients must be suitable and willing to undergo study required biopsies according to the treating institution's own guidelines and requirements, if medically feasible., For all patients in Dose Escalation MUM: uveal melanoma with histologically or cytologically confirmed metastatic disease. Patient must be either treatment naive or have received any number of prior lines and progressed on most recent therapy., For all patients in Dose Escalation Non-MUM: advanced cutaneous or mucosal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies and has evidence of GNAQ/11 mutation based on local data., For patients in Phase II Tebentafusp naïve group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease that has progressed following standard therapies or that has no satisfactory alternative therapies., For patients in Phase II Tebentafusp pre-treated group: Diagnosis of uveal melanoma with histologically or cytologically confirmed metastatic disease. Patients must be previously treated with tebentafusp and have progressed., For patients in Phase II Non-MUM: patients with diagnosis of cutaneous or mucosal melanomas harboring GNAQ/11 mutations based on local data, with histologically or cytologically confirmed metastatic disease that has progressed following all standard therapies or that has no satisfactory alternative therapies.
排除标准
- •Malignant disease, other than that being treated in this study., Active brain metastases, i.e. symptomatic brain metastases or known leptomeningeal disease., Evidence of active bleeding or bleeding diathesis or significant coagulopathy (including familial) or a medical condition requiring long term systemic anticoagulation that would interfere with biopsies., History of anaphylactic or other severe hypersensitivity / infusion reactions to ADCs or monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction., Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes: •= 2 weeks for fluoropyrimidine therapy •= 4 weeks for radiation therapy or limited field radiation for palliation within = 2 weeks prior to the first dose of study treatment. •= 4 weeks or = 5 half-lives (whichever is shorter) for chemotherapy or biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent. •= 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosoureas and mitomycin C. •= 4 weeks for immuno-oncologic therapy, such as CTLA-4, PD-1, or PDL1 antagonists., Clinically significant and / or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade = 2) or clinically significant arrhythmia despite medical treatment.
研究者
相似试验
已完成
1 期
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumorsJPRN-jRCT2080224700ovartis Pharma. K.K.380
进行中（未招募）
1 期
A clinical study to evaluate the efficacy and potential side effects of intravenous PDNO (that releases nitric oxide into the blood stream) in patients with high blood pressure in the lung circulation after heart surgeryAcute Pulmonary HypertensionMedDRA version: 20.0Level: HLTClassification code 10037401Term: Pulmonary hypertensionsSystem Organ Class: 100000004855EUCTR2021-005032-30-SEAttgeno AB40
进行中（未招募）
3 期
An Open-Label, Multicentre Study to Evaluate the Duration of Clinical Remission of Two Courses of Weekly Intramuscular administration of AMEVIVE (alefacept) by evaluating the time to retreatment with AMEVIVE or an alternative systemic therapy in patients with chronic plaque psoriasis in the context of standard dermatological practiceChronic plaque psoriasisSkin - Dermatological conditionsACTRN12605000295640Biogen Idec100
招募中
1 期
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the bodyEUCTR2021-003380-95-ITOVARTIS PHARMA AG124
进行中（未招募）
1 期
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the bodyEUCTR2021-003380-95-DEovartis Pharma AG124